| Literature DB >> 23773277 |
Lan Ma-Hock, Volker Strauss, Silke Treumann, Karin Küttler, Wendel Wohlleben, Thomas Hofmann, Sibylle Gröters, Karin Wiench, Bennard van Ravenzwaay, Robert Landsiedel.
Abstract
BACKGROUND: Carbon nanotubes, graphene, graphite nanoplatelets and carbon black are seemingly chemically identical carbon-based nano-materials with broad technological applications. Carbon nanotubes and carbon black possess different inhalation toxicities, whereas little is known about graphene and graphite nanoplatelets.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23773277 PMCID: PMC3720229 DOI: 10.1186/1743-8977-10-23
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Figure 1Scanning electron microscopy images of the test materials. A-D: agglomerate scale, E-H: primary structure scale. A, E: MWCNT, B, F: graphene, C, G: graphite nanoplatelets, D, H: Carbon Black. Note the same scale for MWCNT and Carbon Black, and slightly different set of scales for graphite nanoplatelets and graphene, in order to point to their individual characteristics.
Figure 2Diagrams of mercury intrusion porosimetry experiments with MWCNT, graphene, graphite nanoplatelets and carbon black.
Physico-chemical parameters of the test materials
| Representative images (SEM) | See Figure | See Figure | See Figure | See Figure | ||||
| Particle size Distribution (SEM)primary structure | 15 nm, fiber shape | Up to 10,000 nm diameter, flakes | Up to 30,000 nm diameter, flakes | 50-100 nm, globular | ||||
| State of agglomeration | ~20,000 nm, bundles | ~40,000 nm, ‘crumpled napkin’ | >50,000, ‘crumpled cardboard’ | >20,000 nm | ||||
| Crystallite size (XRD) | Dominatingly amorphous in XRD | Dominatingly amorphous in XRD | Contains amorphous material, but has sharp diffraction peak corresponding to 19 nm crystallite size | Dominatingly amorphous in XRD | ||||
| Crystalline phase (XRD) | Graphite, C hexagonal with modified lattice const. | Possibly graphite, sync –C– hexagonal or carbon –C– hexagonal, or carbon –C– cubic or carbon - C | Graphite, sync– C - hexagonal | Graphite, C hexagonal with modified lattice const. | ||||
| Pore sizes (Hg intrusion) | 25 nm, 400 nm, 150,000 nm | 9 nm, 100 nm, 40,000 nm | 6,000 nm, 30,000 nm, 150,000 nm | 100 nm, 150,000 nm | ||||
| Surface area (Hg) [mg/m2] | 161 | 131 | 74 | 32 | ||||
| Apparent density (g/mL) | 0.15 | 0.02 | 0.04 | 0.52 | ||||
| Agglomerate density (g/mL) | 0.39 | 0.29 | 0.89 | 1.05 | ||||
| Surface chemistry (%) (XPS) | C | 99 | C | 84.1 | C | 84.3 | C | 98 |
| O | 1 | O | 8.8 | O | 9.0 | O | 1 | |
| | | S | 5.4 | S | 1.7 | S | 1 | |
| | | Na | 0.6 | Na | 3.0 | Cl | <<1 | |
| | | Si | 0.4 | Ca | 1.5 | | | |
| | | Cl | 0.6 | Si | 0.6 | | | |
| Raman peak positions (cm-1) (Laser spectroscopy) | G | 1574 | | 1574 | | 1573 | | 1590 |
| D | 1338 | | 1338 | | 1348 | | 1348 | |
| D/G | 1.16 ± 0.04 | | 1.40 ± 0.05 | | 0.01 ± 0.01 | | - | |
| Dispersability (by AUC) | agglomerated | agglomerated | agglomerated | agglomerated | ||||
| In water | <0.01 wt% below 100 nm | <0.01% below 100 nm | <0.01% below 100 nm | 1,920 nm | ||||
| In DMEM/FCS | agglomerated at several μm | | | Dispersed below 100 nm | ||||
| Purity (combined assessment from XRD, ICP-MS, XPS data) | 99% | < 85% | < 85% | 98% | ||||
| Identified impurities | None significant | Sulfur impurity (presumably from acid intercalation before exfoliation) | Na-, Ca, Si-containing minerals | None significant | ||||
| 3D-Graphite (not 2D-Graphene) impurities | 3D-Graphite (not 2D-Graphene) impurities | |||||||
Results of gravimetric determination of test atmosphere concentration and particle size distribution
| Target concentration (mg/m3) | | 0.1 | 0.5 | 2.5 |
| Measured concentration (mg/m3 ± SD) | | 0.15 ± 0.05 | 0.57 ± 0.10 | 2.86 ± 0.82 |
| MMAD (μm) | | 1.1/1.7 | 1.3/0.9 | 2.0/1.2 |
| GSD | | 3.7/3.0 | 3.7/3.8 | 3.0/3.5 |
| OPC | Count median diameter (μm) | 0.494 | 0.499 | 0.533 |
| Count concentration (N/cm3) | 70 | 405 | 724 | |
| SMPS | Count median diameter (μm) | 0.145 | 0.096 | 0.127 |
| Count concentration (N/cm3) | 1072 | 5636 | 4410 | |
| Graphene | | | | |
| Target concentration (mg/m3) | | 0.5 | 2.5 | 10.0 |
| Measured concentration (mg/m3 ± SD) | | 0.54 ± 0.04 | 3.05 ± 1.05 | 10.1 ± 4.5 |
| MMAD (μm)* | | ≤ 0.4 | < 0.4 | < 0.4 |
| OPC | Count median diameter (μm) | 0.473 | 0.977 | 0.656 |
| Count concentration (N/cm3) | 57 | 191 | 343 | |
| SMPS | Count median diameter (μm) | 0.102 | 0.436 | 0.508 |
| Count concentration (N/cm3) | 269 | 98 | 226 | |
| Graphite nanoplatelets | | | | |
| Target concentration (mg/m3) | | 0.5 | 2.5 | 10 |
| Measured concentration (mg/m3 ± SD) | | 0.46 ± 0.11 | 2.08 ± 0.33 | 10.27 ± 1.44 |
| MMAD (μm) | | 1.7/1.6 | 2.1/2.3 | 2.7/3.4 |
| GSD | | 2.4/2.2 | 2.8/2.5 | 2.7/2.5 |
| OPC | Count median diameter (μm) | 0.373 | 0.373 | 0.360 |
| Count concentration (N/cm3) | 458 | 1828 | 7401 | |
| SMPS | Count median diameter (μm) | 0.123 | 0.146 | 0.148 |
| Count concentration (N/cm3) | 2819 | 9893 | 35606 | |
| Carbon Black | | | | |
| Target concentration (mg/m3) | | 0.5 | 2.5 | 10 |
| Measured concentration (mg/m3 ± SD) | | 0.5 ± 0.1 | 2.5 ± 0.2 | 10.9 ± 1.5 |
| MMAD (μm)/GSD | | 0.9/0.8 | 0.6/0.7 | 0.9/0.6 |
| GSD | | 2.7/2.1 | 3.6/3.1 | 4.5/2.7 |
| OPC | Count median diameter (μm) | 0.40 | 0.38 | 0.38 |
| Count concentration (N/cm3) | 1231 | 7418 | 35829 | |
| SMPS | Count median diameter (μm) | 0.24 | 0.22 | 0.23 |
| Count concentration (N/cm3) | 21138 | 122097 | 371078 |
OPC Optical Particle Counter, SMPS Scanning Mobility Particle Sizer.
* GSD could not be determined (majority below the smallest impactor stage).
Figure 3Scanning electron images of representative test atmosphere samples. A, B: MWCNT, C: graphene, D: graphite nanoplatelets.
Cytology parameters in BALF after exposure to MWCNT
| Concentration [mg/m3] | 0.1 | 0.5 | 2.5 | 0.1 | 0.5 | 2.5 |
| Total Cells | 1.1 | 1.4 | 3.6** | 1.1 | 1.0 | 2.1* |
| Polymorphonuclear Neutrophils | 1.4 | 72.8** | 436.6** | 4.9 | 8.8 | 343.8** |
| Lymphocytes | 0.9 | 5.6 | 41.3** | 1.4 | 3.9 | 9.6** |
| Macrophages | 1.1 | 0.8 | 0.3* | 1.1 | 0.9 | 1.1 |
* Statistically significant, p < 0.05; ** statistically significant, p < 0.01.
Differences are expressed as x-fold ratios compared to the concurrent control group.
Protein concentration and enzyme activities in BALF after exposure to MWCNT
| Concentration [mg/m3] | 0.1 | 0.5 | 2.5 | 0.1 | 0.5 | 2.5 |
| Total Protein | 1.1 | 1.5 | 3.5** | 1.1 | 1.0 | 1.7 |
| GGT | 1.4 | 5.1** | 7.4** | 0.8 | 3.5* | 9.5** |
| LDH | 1.3 | 2.0** | 5.2** | 1.2 | 1.1 | 2.4** |
| ALP | 1.3 | 2.3* | 3.8** | 0.9 | 0.9 | 1.5* |
| NAG | 1.0 | 1.4 | 2.8** | 0.9 | 1.3 | 2.1 |
* Statistically significant, p < 0.05; ** statistically significant, p < 0.01.
Differences are expressed as x-fold ratios compared to the concurrent control group.
Mediators in BALF after exposure to MWCNT
| Concentration [mg/m3] | 0.1 | 0.5 | 2.5 | 0.1 | 0.5 | 2.5 |
| β2-Microglobulin | 1.1 | 1.6** | 2.8** | 1.1 | 1.2 | 2.2** |
| CINC-1/IL-8 | 1.0 | 4.6** | 13.3** | 1.2 | 2.1* | 10.5** |
| Clusterin | 1.5 | 1.9* | 4.4** | 1.0 | 1.1 | 2.2* |
| GCP-2 | 0.9 | 8.1** | 19.9** | 1.6 | 4.0* | 36.2** |
| KC/GROα | 1.5 | 6.3* | 36.9** | 0.7 | 1.6 | 20.8** |
| MCP-1 | 1.0 | 2.3** | 15.8** | 1.5 | 1.6* | 13.5** |
| MCP-3 | 1.0 | 2.5** | 22.3** | 1.6 | 1.7* | 15.9** |
| M-CSF | 1.4 | 4.3** | 9.6** | 1.1 | 1.7* | 3.7** |
| MDC | 1.2 | 6.1 | 50.8** | 1.1 | 1.8 | 20.6** |
| MIP-1β | 0.7 | 1.2 | 3.1** | 1.6 | 1.5 | 4.1** |
| MIP-2 | 1.1 | 2.6** | 4.5** | 1.5 | 1.7* | 5.4** |
| MPO | 1.6 | 29.5* | 193.3** | 1.4 | 1.9 | 65.5** |
| VEGF | 1.1 | 2.1* | 5.0** | 1.0 | 1.0 | 1.6 |
* Statistically significant, p < 0.05; ** statistically significant, p < 0.01.
Differences are expressed as x-fold ratios compared to the concurrent control group.
Mediator levels in lung tissue after exposure to MWCNT
| Concentration [mg/m3] | 0.1 | 0.5 | 2.5 | 0.1 | 0.5 | 2.5 |
| CINC-1/IL-8 | 1.2 | 3.0** | 6.8** | 1.0 | 1.9* | 4.6** |
| KC/GROα | 2.0 | 9.7** | 21.3** | 1.0 | 3.3* | 18.8** |
| MCP-1 | 1.1 | 1.2 | 3.1** | 0.8 | 0.9 | 1.8* |
| MCP-3 | 0.9 | 1.0 | 2.2** | 0.9 | 1.0 | 1.7* |
| M-CSF | 1.2 | 1.5* | 2.3** | 1.1 | 1.2* | 1.6** |
| MDC | 1.4 | 2.1 | 8.8** | 0.9 | 1.0 | 2.6* |
| MIP-2 | 1.2 | 2.5** | 5.1** | 0.9 | 1.4* | 4.2** |
| MPO | 1.3 | 1.3 | 2.2** | 1.1 | 1.0 | 1.3 |
| NGAL | 1.4* | 2.2** | 4.7** | 1.1 | 1.2 | 2.9** |
| Osteopontin | 1.1 | 1.6 | 3.1** | 0.6 | 0.9 | 2.9** |
* Statistically significant, p < 0.05; ** statistically significant, p < 0.01.
Differences are expressed as x-fold ratios compared to the concurrent control group.
Cytology parameters in BALF after exposure to graphene
| Concentration [mg/m3] | 0.5 | 2.5 | 10 | 0.5 | 2.5 | 10 |
| Total Cells | 0.9 | 0.7 | 1.7 | 1.0 | 1.3 | 1.5** |
| Eosinophils | 0.5 | 1.4 | 8.2** | 1.7 | 2.3 | 0.0 |
| Polymorphonuclear Neutrophils | 1.2 | 7.5* | 102.8** | 1.0 | 3.0* | 16.5** |
| Lymphocytes | 3.0 | 4.2 | 33.4** | 1.9 | 2.7 | 5.7** |
| Macrophages | 0.8 | 0.6 | 0.6 | 1.0 | 1.2 | 1.2 |
* Statistically significant, p < 0.05; ** statistically significant, p < 0.01.
Differences are expressed as x-fold ratios compared to the concurrent control group.
Protein concentration and enzyme activities in BALF after exposure to graphene
| Concentration [mg/m3] | 0.5 | 2.5 | 10 | 0.5 | 2.5 | 10 |
| Total Protein | 1.3 | 1.2 | 2.9 | 1.2 | 1.4* | 1.8** |
| GGT | 1.0 | 4.4 | 10.3** | + | + | + |
| LDH | 0.9 | 1.1 | 2.8 | 1.2 | 1.6* | 2.2** |
| ALP | 1.1 | 1.5* | 3.2** | 1.2 | 1.0 | 1.9** |
| NAG | 1.0 | 1.2 | 1.8 | 0.8 | 1.0 | 1.1 |
* Statistically significant, p < 0.05; ** statistically significant, p < 0.01.
+: Increased compared to controls (activity below detection limit in controls).
Differences are expressed as x-fold ratios compared to the concurrent control group.
Mediator levels in BALF after exposure to graphene
| Concentration [mg/m3] | 0.5 | 2.5 | 10 | 0.5 | 2.5 | 10 |
| CINC-1/IL-8 | 1.4 | 2.3** | 5.9** | 1.2* | 1.7* | 3.9** |
| MCP-1 | 2.0 | 1.5* | 11.1** | 1.1 | 1.7* | 4.6** |
| Osteopontin | 2.3* | 1.8 | 13.1** | 1.8* | 4.6** | 18.6** |
* Statistically significant, p < 0.05; ** statistically significant, p < 0.01.
Differences are expressed as x-fold ratios compared to the concurrent control group.
Mediator levels in lung tissue after exposure to graphene
| Concentration [mg/m3] | 0.5 | 2.5 | 10 | 0.5 | 2.5 | 10 |
| IL-1α | 1.2 | 1.6** | 3.0** | 1.0 | 1.4 | 1.6 |
** Statistically significant, p < 0.01.
Differences are expressed as x-fold ratios compared to the concurrent control group.
Figure 4Comparison of changes in BALF parameters after exposure to MWCNT and graphene. Changes are shown as x-fold differences compared to controls using a logarithmic scaling.
Figure 5Microscopic appearance of lungs (A-E) and lymph node (F). A – Control. B – MWCNT, 2.5 mg/m3, study day 4: Microgranuloma, particles in the lesion and inside of alveolar macrophages. C – Graphene, 10 mg/m3, study day 7: Microgranuloma, particles within the lesion. D – Graphite nanoplatelets, 10 mg/m3, study day 4: Particles inside of alveolar macrophages. E – Carbon Black, 10 mg/m3, study day 4: Particles inside of alveolar macrophages. F – MWCNT, 2.5 mg/m3, study day 25: Mediastinal lymph nodes with macrophages containing black particles (arrow).
Dosimetry and calculated surface and volume lung burden
| Highest target concentration [mg/m3] | 2.5 | 10 | 10 | 10 |
| Hg surface area [m2/g] | 161 | 131 | 74 | 32 |
| Apparent density [g/mL] | 0.15 | 0.04 | 0.02 | 0.52 |
| Calculated deposition using apparent density [mg/lung]* | 0.03 | 0.26 | 0.20 | 0.10 |
| Calculated volumetric lung burden using apparent density [μL/lung]** | 0.19 | 4.79 | 3.67 | 0.50 |
| Agglomerate density [g/mL] | 0.39 | 0.29 | 0.89 | 1.05 |
| Calculated deposition using agglomerate density [mg/lung]* | 0.03 | 0.30 | 0.11 | 0.33 |
| Calculated volumetric lung burden using agglomerate density [μL/lung]** | 0.07 | 1.02 | 0.52 | 0.31 |
| Calculated surface lung burden using agglomerate density [m2/lung] | 0.005 | 0.039 | 0.008 | 0.010 |
| Pulmonary response | +++ | + | (−) | - |
* Calculated with Multiple-Path Particle Dosimetry Model (MPPD v 2.11).
** Based on calculated disposition data.
Figure 6Correlation of polymorphonuclear neutrophils in BALF with calculated lung burden on study day 7.
Figure 7Schematic picture of the Inhalation exposure system. Aerosols of MWCNT, graphite nanoplatelets, and Carbon Black were generated with a brush generator (top); graphene was dispersed via a swinging bed generator (bottom).